These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

306 related articles for article (PubMed ID: 22022980)

  • 1. Advances in hepatitis C virus vaccines, Part one: Advances in basic knowledge for hepatitis C virus vaccine design.
    Roohvand F; Kossari N
    Expert Opin Ther Pat; 2011 Dec; 21(12):1811-30. PubMed ID: 22022980
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Advances in hepatitis C virus vaccines, part two: advances in hepatitis C virus vaccine formulations and modalities.
    Roohvand F; Kossari N
    Expert Opin Ther Pat; 2012 Apr; 22(4):391-415. PubMed ID: 22455502
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Progress in the development of preventive and therapeutic vaccines for hepatitis C virus.
    Torresi J; Johnson D; Wedemeyer H
    J Hepatol; 2011 Jun; 54(6):1273-85. PubMed ID: 21236312
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Methods to Evaluate Novel Hepatitis C Virus Vaccines.
    Ahlén G; Frelin L
    Methods Mol Biol; 2016; 1403():221-44. PubMed ID: 27076133
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prospects for prophylactic and therapeutic vaccines against hepatitis C virus.
    Feinstone SM; Hu DJ; Major ME
    Clin Infect Dis; 2012 Jul; 55 Suppl 1():S25-32. PubMed ID: 22715210
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Hepatitis C virus vaccine].
    Wakita T
    Nihon Rinsho; 2008 Oct; 66(10):1961-4. PubMed ID: 18939497
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Neutralizing antibodies induced by cell culture-derived hepatitis C virus protect against infection in mice.
    Akazawa D; Moriyama M; Yokokawa H; Omi N; Watanabe N; Date T; Morikawa K; Aizaki H; Ishii K; Kato T; Mochizuki H; Nakamura N; Wakita T
    Gastroenterology; 2013 Aug; 145(2):447-55.e1-4. PubMed ID: 23673355
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Complete definition of immunological correlates of protection and clearance of hepatitis C virus infection: a relevant pending task for vaccine development.
    Alvarez-Lajonchere L; Dueñas-Carrera S
    Int Rev Immunol; 2012 Jun; 31(3):223-42. PubMed ID: 22587022
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [The development of therapeutic vaccine for hepatitis C virus].
    Kimura K; Kohara M
    Gan To Kagaku Ryoho; 2012 Oct; 39(10):1451-7. PubMed ID: 23064054
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Hepatitis C Virus Vaccine Research: Time to Put Up or Shut Up.
    Hartlage AS; Kapoor A
    Viruses; 2021 Aug; 13(8):. PubMed ID: 34452460
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A novel combined vaccine candidate containing epitopes of HCV NS3, core and E1 proteins induces multi-specific immune responses in BALB/c mice.
    Zeng R; Li G; Ling S; Zhang H; Yao Z; Xiu B; He F; Huang R; Wei L
    Antiviral Res; 2009 Oct; 84(1):23-30. PubMed ID: 19646486
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Oral immunization with attenuated Salmonella carrying a co-expression plasmid encoding the core and E2 proteins of hepatitis C virus capable of inducing cellular immune responses and neutralizing antibodies in mice.
    Cao J; Chen Z; Ren Y; Luo Y; Cao M; Lu W; Zhao P; Qi Z
    Vaccine; 2011 May; 29(20):3714-23. PubMed ID: 21396407
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Therapeutic vaccines against hepatitis C virus.
    Xue J; Zhu H; Chen Z
    Infect Genet Evol; 2014 Mar; 22():120-9. PubMed ID: 24462908
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Conserved hepatitis C virus sequences are highly immunogenic for CD4(+) T cells: implications for vaccine development.
    Lamonaca V; Missale G; Urbani S; Pilli M; Boni C; Mori C; Sette A; Massari M; Southwood S; Bertoni R; Valli A; Fiaccadori F; Ferrari C
    Hepatology; 1999 Oct; 30(4):1088-98. PubMed ID: 10498664
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Hepatitis C vaccine: supply and demand.
    Strickland GT; El-Kamary SS; Klenerman P; Nicosia A
    Lancet Infect Dis; 2008 Jun; 8(6):379-86. PubMed ID: 18501853
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Chimeric hepatitis B virus/hepatitis C virus envelope proteins elicit broadly neutralizing antibodies and constitute a potential bivalent prophylactic vaccine.
    Beaumont E; Patient R; Hourioux C; Dimier-Poisson I; Roingeard P
    Hepatology; 2013 Apr; 57(4):1303-13. PubMed ID: 23150224
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prospects for a vaccine against the hepatitis C virus.
    Houghton M; Abrignani S
    Nature; 2005 Aug; 436(7053):961-6. PubMed ID: 16107836
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Virus-like particle-based vaccines against hepatitis C virus infection.
    Bellier B; Klatzmann D
    Expert Rev Vaccines; 2013 Feb; 12(2):143-54. PubMed ID: 23414406
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Development of a heterologous, multigenotype vaccine against hepatitis C virus infection.
    Encke J; Radunz W; Eisenbach C; Geib J; Gehrke S; Pfaff E; Stremmel W
    Eur J Clin Invest; 2007 May; 37(5):396-406. PubMed ID: 17461986
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Vaccines and immunotherapies against hepatitis B and hepatitis C viruses.
    Inchauspé G; Michel ML
    J Viral Hepat; 2007 Nov; 14 Suppl 1():97-103. PubMed ID: 17958650
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.